Annett, S., Moore, G., Short, A., Marshall, A., McCrudden, C., Yakkundi, A., Das, S., McCluggage, W. G., Nelson, L., Harley, I., Moustafa, N., Kennedy, C. J., deFazio, A., Brand, A., Sharma, R., Brennan, D., O’Toole, S., O’Leary, J., Bates, M., O’Riain, C., O’Connor, D., Furlong, F., McCarthy, H., Kissenpfennig, A., McClements, L. and Robson, T. (2019) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British journal of cancer 2019, Feb;122(3):361-371. PMID: 31772325.

McCrudden, C.M., McBride, J.W., McCaffrey, J., McErlean, E.M., Dunne, N.J., Kett, V.L., Coulter, J.A., Robson, T., McCarthy, H.O.  (2018). Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancerCancer Nanotechnol.9(1):5. PMID: 29899810.

Cole, G., Ali, A.A., McCrudden, C.M., McBride, J.W., McCaffrey, J., Robson, T., Kett, VL., Dunne NJ, Donnelly RF, McCarthy HO. (2018) DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.    Eur. Journal of Pharm Biopharm.127:288-297   PMID:29510205.  (IF:4.1)

Byrne, T., Nelson, L., Beirne, J.P., Sharpe, D., Quinn, J.E., McCluggage, W.G., Robson, T., Furlong, F. (2018) BRCA1 and MAD2 are co-expressed and are prognostic indicators in ovarian/tubal high-grade serous carcinoma.Int. Journal of Gynecol. Cancer.28(3):472-478. PMID: 29465507.(IF:2.3)

O’Sullivan, J.M., Preston, R.J.S., Robson, T., O’Donnell, J.S. (2018) Emerging Roles for von Willebrand Factor in Cancer Cell Biology.  Semin Thromb Hemost. 44(2):159-166. PMID: 29165741. (IF:3.6)

McCrudden, C., McBride, J., McCaffrey, J., Ali, A., Dunne, N., Kett, V., Coulter, J., Robson, T.,McCarthy, H. (2017) Systemic RALA/iNOS nanoparticles; a potent gene therapy for metastatic breast cancer coupled as a biomarker of treatmentMol Ther Nucleic Acids.6:249-258.PMID:28325291.

Ali, A.A., McCrudden, C.M., McCaffrey, J., McBride, J.W., Cole, G., Dunne, N.J., Robson T., Kissenpfennig, A., Donnelly, R.F., McCarthy, H.O . (2017)  DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomedicine.13(3):921-932.  PMID: 27979747. (IF: 6.7)   

El-Helali, A.,  Plummer, R., Jayson, G.,  Coyle, V., Rogers, C.,  D’Arcangelo, M.,  Graham, D.M., Drew, Y.,  Clamp, A.,  McCann, J., McCavigan, A.,  Knight, L.,  McCabe, N., Keating, K.,  Dyer, R.,  Harrison, T., Harkin, P.,  Robson, T.,  Kennedy, R., Wilson, R. (2016) A biomarker-guided first-in-human trial of subcutaneous ALM201 in patients with solid tumoursAnnals of Oncology,27(6):143TiP.  (IF: 11.8)

Massey, A.S., Pentlavalli, S., Cunningham, R., McCrudden, C.M., McErlean, E.M., Redpath, P., Ali, A.A., Annett, S., McBride, J.W., McCaffrey, J., Robson T., Migaud, M.E., McCarthy, H.O. (2016) Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALAMol Pharm.13(4):1217-28.PMID: 26954700. (IF: 4.1) 

Armstrong, C.W., Maxwell P.J., Ong C.W., Redmond K.M., McCann C., Neisen J., Ward G.A., Chessari, G., Johnson, C, Crawford, N.T., LaBonte, M.J., Prise, K.M., Robson, T., Salto-Tellez, M, Longley, D.B., Waugh, D.J. (2016) PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapyOncotarget. 16;7(7):7885-98.   PMID: 26799286.      (IF: 5.1)

Lawler, M., Gavin, A., Salto-Tellez, M., Kennedy, R.D., Van Schaeybroeck, S., Wilson, R.H., Harkin, D.P., Grayson, M., Boyd, R.E., Hamilton, P.W., McArt, D.G., James, J., Robson, T., Ladner, R.D., Prise, K.M., O’Sullivan, J.M., Harrison, T., Murray, L., Johnston, P.G., Waugh, D.J. (2016) Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer ProgramCancer. 122(5):664-73. PMID: 26695702.(IF: 5.6)

McBride, J.W., Massey, A.S., McCaffrey, J., McCrudden, C.M., Coulter, J.A., Dunne, N.J.,Robson, T., McCarthy, H.O. (2016). Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer.  Int J Pharm 500(1-2):144-53.PMID: 26802497.      (IF: 3.6)

McCaffrey, J., McCrudden, C.M., Ali, A.A., Massey, A.S., McBride, J.W., McCrudden, M.T., Vicente-Perez, E.M., Coulter, J.A., Robson, T., Donnelly, R.F., McCarthy, H.O. (2016). Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device.  J Control Release. 28;226:238-47.    PMID: 26883753.     (IF: 7.8)        

Bennett,R., Yakkundi, A.,McKeen,H.D., McClements,L., McKeogh,T.J., Arthur,K., Robson,T.,McCarthy,H.O. (2015) RALA-mediated delivery of FKBPL nucleic acid therapeutics.Nanomedicine (Lond).  10(19):2989-3001.   PMID: 26419658.( IF:6.2) 

Nelson, L., McKeen, H.D., Marshall, A., Mulrane, L., Starczynski,J., Storr, S.J., Lanighan, F., Byrne, C., Arthur, K., Hegarty, S., Abdunnabi, Ali, A., Ellis, I.O., Green, A.R., Rakha, E., Young, L., Kunkler, I., Thomas, J., Jack, W., Cameron, D., Jirström, K., Yakkundi, A., McClements, L., Martin, S.G., Gallagher, W., Dunn, J., Bartlett, J., O’Connor, D., Robson, T. (2015) Evaluating the prognostic potential of FKBPL; a novel breast cancer biomarker.Oncotarget6(14): 12209-12223.PMID: 25767277.    (IF: 6.4) 

Yakkundi,A., Bennett,R., Hernàndez-Negrete,I., Delalande,J.-M., Hanna,M., Lyubomska,O., Arthur,K., McKeen,H.D., Nelson, L., McClements, L., McCrudden,C.M., McCarthy,H.O., Burns,A., Bicknell, R., Kissenpfennig,A., Robson,T.(2015) FKBPL is a critical anti-angiogenic regulator having an essential role in developmental and pathological angiogenesisArtiosclerosis Thrombosis and Vascular Biology35(4):845-54. PMID: 25767277.    (IF: 6.4)

McCrudden, C.M.,  O’Rourke, M.G., Cherry, K.E., Yuen, H-F., O’Rourke, D., Babur, M., Telfer, B.A., Thomas, H.D., Keane, P., Nambirajan, T., Hagan, C., O’Sullivan, J.M., Shaw, C.,  Williams, K.J., Curtin, N.J., Hirst, D.G., Robson, T.(2015). Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin 2 light chain kinase, P2 receptors, and PARP itselfPLoS ONE10(2):e0118187. doi: 10.1371/journal.pone.0118187. PMID: 25689628.  (IF:3.23)

McCarthy, H.O., McCaffrey, J., McCrudden, C.M., Zholobenko, A., Alia, A.A., McBride, J., Massey, A., Pentlavalia, S., Chen, K-H, Cole, G., Loughran, S., Dunne, N.J., Donnelly, R.F., Kett, V.L., Robson, T. (2014) Development and characterisation of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene deliveryJ Control Release.189:141-9 (PMID: 24995949.    (IF:7.7)

Donley, C.,  McClelland, K., McKeen, H.D., Nelson, L., Yakkundi, A., Jithesh, P.V., Burrows, J., McClements, L.,Valentine, A., Prise, K.M., McCarthy, H.O., Robson, T.(2014) Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.Oncogene33(26):3441-50.PMID: 23912458.  (IF:8.46)

McClements, L., Yakkundi, A., Papaspyropoulos, A., Harrison, H., Ablett, M.P., Jithesh, P.V., McKeen, H.D., Bennett, R., Donley, C., Kissenpfennig, A., McIntosh, S., McCarthy, H.O., O’Neill, E., Clarke, R.B., Robson, T. (2013) Targeting treatment resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathwayClin Cancer Res19(14):3881-93.  PMID: 2374106.   (IF:8.72)

Yakkundi, A., McCallum, L., O’Kane, A., Dyer, H., Worthington, J., McKeen, H.D., McClements, L., Elliott, C., McCarthy, H.O,  Hirst, D.G, Robson T.(2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: Regulation of CD44 and the cytoskeletal pathwayPLoS ONE.8(2): e55075. doi:10.1371/journal.pone.0055075.PMID: 23457460.    (IF:3.23)

McCluskey, A.G., Mairs, R.J., Sorensen, A., Robson, T., McCarthy, H.O., Pimlott SL, Babich JW, Champion S, Boyd M. (2013) Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) PromoterRadiat Res.179(3):282-92. PMID: 23336184. (IF:2.91)     

Ali, A.A., Coulter, J.A., Ogle, C.H., Migaud, M.M., Hirst, D.G., Robson, T., McCarthy, H.O. (2013) The contribution of N2O3to the cytotoxicity of the nitric donor drug DETA/NO; an emerging role for S-nitrosylationBiosci Rep.28;33(2). PMID: 23402389.      (IF: 2.63)

McKeen, H.D., Brennan, D.J., Hegarty, S., Lanigan, F., Jirstrom, K., Byrne, C., Yakkundi, A., McCarthy, H.O., Gallagher, W.M., Robson, T. (2011) The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPLBiochem Soc Trans39(2):663-8. PMID: 21428958.  (IF: 3.19)

Valentine, A., O’Rourke, M., Yakkundi, A., Worthington, J., Hookham, M., Bicknell, R., McCarthy, H., McClelland, K., McCallum, L., Dyer, H., McKeen, H., Waugh, D., Roberts, J., McGregor, J., Cotton, G., James, I., Harrison, T., Hirst, D., Robson, T.(2011). FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanismClinicalCancer Research17(5):1044-56. PMID: 21364036.     (IF: 9.6)

McCarthy, H.O., Zholobenko, A.V., Wang, Y., Canine, B., Robson, T., Hirst, D.G., Hatefi, A. (2011). Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy.Intern. J. Pharm.405(1-2):196-202.  PMID: 21134429.   (IF: 3.6)   

Coulter, J.A., Page, N.L., Worthington, J., Robson, T., Hirst, D.G., McCarthy, H.O. (2010). Nitric oxide synthase gene therapy for prostate cancer under the control of the human osteocalcin promoterGene Therapy 12(9): 755-765.  PMID: 20821746.   (IF: 2.5)

McKeen, H.D., Byrne, C., Jithesh,P.V., Donley,C., Valentine,A., Yakkundi,A., O’Rourke,M., Swanton,C., McCarthy,H.O., Hirst,D.G., RobsonT. (2010) FKBPL regulates estrogen receptor signaling and determines response to endocrine therapyCancer Research70(3):1090-1100. PMID: 20103631.   (IF 9.3)

Sunnotel,O., Hiripi,L., Lagan,K., McDaid,J., De León, J.M., Miyagawa, Y, Crowe,H., Kaluskar,S, Ward,M., Scullion,C., Campbell,A., Downes,S.C., Hirst,D.G., Barton,D., Mocanu,E., Tsujimura,A.,  Cox,M.B., Robson,T.and Walsh,C.P. (2010) Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control studyReproductive Biology and Endocrinology8;8(1):22.  PMID: 20210997.      (IF: 2.8)

Devlin, A.H., Thompson, P., Robson, T., McKeown, S.R. (2010) Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translationMolecular Carcinogenesis 49(2):190-199. PMID: 19908239.   (IF: 4.18)

Adams, C., McCarthy, H.O., Coulter, J.A., Worthington, J., Murphy, C., Robson, T., Hirst, D.G. (2009) Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.Journal of Gene Medicine11(2):160-8. PMID: 19062185.     

Ali, M., Telfer, B.A., McCrudden, C., O’Rourke, M., Thomas, H.D., Kamjoo, M., Kyle, S., Robson, T., Shaw C, Hirst DG, Curtin NJ, Williams KJ (2009) Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 15(19):6106-12. PMID: 19789326.      

Devlin, A.H.,McIlroy, M.,McKeen, H.D.,Bonde, P., Menezes, A.A.,Swarbrick, C.J., Robson, T., Hirst, D.G.,Campbell, F.C.,McGuigan, J.A.,McKeown, S.R. (2009) Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal refluxMolecular Carcinogenesis48(2):110-7. PMID: 18618592.     

O’Rourke, M., Ward, C., McKenna, J., Worthington, J., Valentine, A., Robson, T, Hirst, D.G, McKeown SR (2008) Evaluation of the anti-angiogenic potential of AQ4NClinical Cancer Research14(5):1502-9.  PMID: 18316575.      

Coulter, J.A.,McCarthyH.O., Worthington,J.,Robson,T.,  Scott,S. and Hirst,D.G. (2008) The radiation inducible pE9 promoter driving inducible nitric oxide synthase radiosensitises hypoxic tumour cells to radiationGene Therapy15(7):495-503.  PMID: 18256696.      

Butterworth,K.T., McCarthy,H.O., Devlin,A., Ming,L.,Robson,T., McKeown,S.R., Worthington,J. (2008) Hypoxia selects for androgen independent LNCaP cells with a more malignant geno and phenotypeInt J Cancer123(4):760-768. PMID: 18512241.

Coulter, J.A., McCarthy, H.O., Xiang, J., Roedl, W., Wagner, E., Robson, T., Hirst, D.G.(2008)Nitric oxide – a novel therapeutic for cancerNitric Oxide19(2):192-8. PMID: 18485922.      

McKeen, H., Byrne, C., Valentine, A., O’Rourke, M., Yakkundi, M., McClelland, K.,  McAlpine, L., Hirst, DG., and Robson, T. (2008)   Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival.Breast Cancer Research10:1-1

Marignol, L., Robson, T., McCarthy, H.O., Worthington, J., Murray, M., Hollywood, D., Lawler, M, Hirst D. (2008) The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? Journal of Gene Medicine 10(9):1032-1038. PMID: 18615772.      

McKeen, H.D., McAlpine, K., Valentine, A., Quinn, D.J., McClelland, K., Byrne, C., O’Rourke, M., Young, S., Scott, C.J., McCarthy, H.O., Hirst, D.G. and Robson, T.(2008) A novel FK506-like binding protein (FKBPL) interacts with the glucocorticoid receptor and regulates steroid receptor signallingEndocrinology149(11):5724-34.  PMID: 18669603.      

McCarthy, H.O., Coulter, J.A., Worthington, J., Robson, T.,Hirst, D.G. (2007) Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancerJournal Gene Med.9(6):511-20. PMID: 17471586.      

McCarthy,H.O., Worthington,J., BarrettE.,Cosimo,E., Boyd,M., Mairs,R.J., Ward,C., McKeown,S.R., Hirst,D.G. and Robson, T. (2007) p21(WAF-1)-mediated transcriptional targeting of iNOS gene therapy sensitizes tumours to fractionated radiotherapy.Gene Therapy14(3):246-55.  PMID: 17006546.      

Jasim, Z.F., Lioe,L.F., McKenna,  K.E., Robson, T.and Ouhtit, A. (2006) The effect of UVB (TL-01) phototherapy on epidermal expression of p53 protein in psoriatic plaques.Photodermatology Photoimmunology & Photomedicine 22(1):12-7.  PMID: 16436176.      

Yakkundi, A., McErlane, V., Ward, C., McCarthy, H.O., Hughes, C.M., Murray, M., Patterson, L.H., Hirst, D.G., McKeown, S.R., Robson, T.(2006). Tumour hypoxia selective drug activation; a GDEPT approach utilizing cytochrome P450 1A1 and AQ4NCancer Gene Therapy13(6):598-605. PMID: 16410820.    

McIlroy, M.,O’Rourke, M.,McKeown, S.R.,Hirst. D.G.,Robson, T. (2006) Pericytes influence endothelial cell growth characteristics: Role of plasminogen activator inhibitor type 1 (PAI-1)Cardiovasc Research69(1):207-17.  PMID: 16165110.      

Worthington, J., Robson, T., Scott, S. and Hirst, D.G. (2005) Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancerGene Therapy12(19):1417-23.PMID: 15902277.

McErlane, V., Yakkundi, A., Ward, C., McCarthy, H.O., Hughes, C.M., Patterson, L.H., Hirst, D.G., Robson, T., McKeown, S.R. (2005) A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4NJournal Gene Med.7(7):851-9. PMID: 15712360.

Dunne, A.L., Mothersill, C, Robson,T.and Hirst, D.G. (2004) Radiosensitisation of colon cancer cell lines by docetaxel: mechanisms of action Oncology Research – Anticancer drug design14(9):447-54.PMID: 15490976.

Worthington, J., McCarthy, H.O., Barrett, E., Robson, T.and Hirst, D.G. (2004) Direct cytotoxicity and radiosensitization of RIF-1 murine tumours after iNOS gene transfer driven by the radiation inducible WAF1 promoterJournal of Gene Medicine(6):673-80.PMID: 15170738.

Dunne A.L., Price, M.E., Mothersill, C., McKeown, S.R., Robson, T, Hirst, D.G. (2003) The relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cellsBritish Journal of Cancer89(12) 2277-2283.

McKeown, S.R., Robson, T, Price, M.E., Ho, E.T.S., Hirst, D.G. and McKelvey-Martin, V.J. (2003). A modified alkaline comet assay predicts for bladder cancer cell line radiosensitivity.  British Journal of Cancer89(12) 2264-2270.  PMID: 14676804.  

McCarthy, H.O., Hughes, C., Keilty, G., Murray, M, Patterson, L.H., Hirst D.G., McKeown S.R.,Robson T.(2003). Bioreductive GDEPT using cytochrome P4503A4 in combination with AQ4NCancer Gene Therapy10 (1), 40-8.PMID: 12489027.

Worthington, J., Robson,T., O’Keeffe, M., and Hirst, D.G.  (2002). Tumour cell radiosensitisation using a constitutive (CMV) and radiation inducible promoter (WAF1) to drive the iNOS gene; a novel suicide gene therapyGene Therapy9, 263-269.PMID: 11896465.

Al-Assar, O., Robson T., McKeown S.R., Gardin I., Wilson G.D. and Hirst, D.G. (2000) Regulation of c-fos by different compartmental stresses induced by low levels of ionizing radiation.  Radiation Research154(5), 503-514.PMID: 11025647.

Worthington, J., Robson, T., Murray, M., O’Rourke, M., Keilty, G. and Hirst, D.G. (2000). Modification of vascular tone using iNOS under the control of a radiation-inducible promoter.  Gene Therapy7(13) 1126-1131.PMID: 10918479.

Robson, T., Price, M.E., Moore, M.L., Joiner, M.C., McKelvey-Martin, V.J., McKeown, S.R. and Hirst, D.G. (2000).  Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications induced radioresistanceInternational Journal of  Radiation Biology76, 617-623.  PMID: 10866283.

Martin, A.R., Bailie, J.R., Robson, T., McKeown, S.R. Al-Assar, O., and Hirst, D.G. (2000) Retinal pericytes control expression of nitric oxide synthase and endothelin-1 in microvascular endothelial cellsMicrovascular Research.59,131-139.

Price, M.E., McKelvey-Martin, V.J., Richie, J.L., Robson, T. and McKeown, S.R. (2000) DNA double strand break induction and rejoining in bladder tumour cell lines.  Radiation Research.153, 6, 788-795.  PMID: 10625580.

Robson, T., Joiner, M.C., Wilson, G.D., McCullough, W., Price, M.E., McKeown, S.R. and Hirst, D.G. (1999) A novel human stress response related gene with a role in induced radioresistanceRadiation Research 152,451-461.  PMID: 10521921.

Arrand, J.E., Singh, B., Robson, T., Gamble, S.C. and Joiner, M.C. (1997) Molecular dissection of X-ray induced responses in human cellsIn: Les Editions de Physique, Numero special de Radioprotection32, 311-31.

Bailie, J.R., Robson, T., McCullough,W. and Hirst, D.G.  (1997) Identification of the inducible nitric oxide synthase gene in macro and microvascular endothelial cell linesBiochemical Journal Transactions25, 129S. PMID: 9057027.

Robson, T., Lohrer, H., Bailie, J.R., Hirst, D.G., Joiner, M.C. and Arrand, J.E. (1997) Gene regulation by low-dose radiation in a human lung epithelial cell lineBiochemical Journal Transactions25, 335-341. PMID: 9056895.   

Joiner, M.C, Lambin, P, Malaise, E.P, Robson, T, Arrand, J.E., Skov, K.A. and Marples, B. (1996) Hypersensitivity to very low single radiation doses: its relationship to the adaptive response and induced radioresistanceMutation Research358, 171-183. PMID: 8946022.

Robson, T, Lohrer, H., Hirst, D.G., Joiner, M.C. and Arrand, J. E. (1995) Modulation of gene expression by low dose ionizing radiation.  Radiation Research14, 112-113. 

Robson T, Grindley H., Hall A., Vormoor J and Lohrer H. (1994) Increased DNA repair capacity and the modulation of two proteins in a metallothionein overexpressing Chinese hamster ovary cell lineMutation ResearchDNA repair, 314, 143-157. PMID: 7510364.

Robson, T., Hall, A. and Lohrer, H. (1992) Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene   Mutation Research, DNA Repair274, 177-185. PMID: 1380651.

Lohrer, H, Robson, T, Grindley, H, Foster, S. and Hall, A. (1990) Differential effects on cell killing in metallothionein overexpressing CHO mutant cell linesCarcinogenesis,11, 1937-1941. PMID: 2225325.

Lohrer, H. and Robson, T. (1989) Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agentsCarcinogenesis,10, 2279 – 2284. PMID: 2480189.


Annett, S., Moore, G., Robson, T. (2020) FK506 Binding Proteins and Inflammation rRelated Signalling Pathways; Basic Biology, Current Status and Future Prospects for Pharmacological Intervention. Pharmacol Ther. (IF: 9.396).

Moore, G., Annett, S., McClements, L., Robson, T. (2020). Top Notch Targeting Strategies in Cancer: a Detailed Overview of Recent Insights and Current Perspectives. Cells.  9(6), 1503; (registering DOI). (IF: 5.656).

Annett, S., Robson, T.  (2018). Targeting cancer stem cells in the clinic: Current status and perspectivesPharmacol Ther.2018 Jul;187:13-30.    Review.PMID: 29421575.  (IF:11.127).

McClements, L., Annett, S., Yakkundi, A., and Robson, T. (2015) Role of PPIases in ageing and vascular diseasesCurr Mol Pharmacol.9(2):165-79. PMID: 25986561.   (IF:4.4).

Robson, T., James, I.F. (2012) The therapeutic and diagnostic potential of FKBPL; a novel anticancer proteinDrug Discov Today. 17(11-12):544-8. PMID: 22265918.

Hirst, D.G., andRobson, T. (2011)Nitric oxide physiology and pathologyMethods Mol Biol.704:1-13.  PMID: 21161625.  

Hirst, D.G., andRobson, T.(2010) Nitrosative stress as a mediator of apoptosis: implications for cancer therapy.  Curr Pharm Des16 (1): 45-55(11). PMID: 20214617.

Hirst, D.G.,Robson, T. (2010) Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapyCurrent Pharmaceutical Design 16(4):411-420(10).

McCarthy, H.O., Coulter, J.A., Robson, T.and Hirst, D.G. (2008) Inducible Nitric Oxide Synthase Gene Therapy; a tool for the treatment of a diverse range of pathological conditionsJournal of Pharmacy and Pharmacology60(8):999-1017. PMID: 18644193.

Hirst, D.G., Robson, T.(2007) Nitrosative stress in cancer therapyFront Biosci.12:3406-18.  PMID: 17485309.

Hirst, D., Robson, T. (2007) Targeting nitric oxide for cancer therapyJournal of Pharm Pharmacol.59(1):3-13. PMID: 17227615.

Robson, T., Worthington, J., McKeown, S.R., Hirst, D.G. (2005) Radiogenic therapy: novel approaches for enhancing tumour radiosensitivityTechnol Cancer Res Treat.4(4):343-61. PMID: 16029055.

McKeown, S.R., Ward, C. and Robson, T.(2004) Gene directed enzyme prodrug therapy (GDEPT) – a current assessment.Curr Opin Mol Ther.6(4): 421-435.

Robson, T.and Hirst, D.G. (2003) Transcriptional targeting in cancer gene therapy.  Journal of Biomed Biotechnol. 2, 110-137.PMID: 12721516.

Patterson, L.H., McKeown, S.R., Robson, T., Gallagher, R., Raleigh, S. and Orr, S. (1999) Antitumour prodrug development using cytochrome P450 mediated activation Anticancer Drug Design 14, 473-486.


Yakkundi, A., Robson, T., McKeen, H.D. (2013).  Steroid Receptor Signalling in Cancer: a Focus on FK506-Binding Proteins. In: Recent Research Developments in Endocrinology, SG Pandalai (Managing ed.) Research Signpost, Transworld Research Network, Kerala, India.

Hirst, D.G., Robson, T.(2010) Nitric oxide: monotherapy or sensitiser to conventional cancer treatments? In: Nitric Oxide and Cancer: Prognosis, Prevention and Therapy, B. Bonavida, (ed), (ISBN: 978-1-4419-1431-6).

Robson, T., Joiner M.C., Wilson, G.D., McCullough, W., Price, M.E., McKeown, S.R., Hirst, D.G. (1999). A novel human stress response-related gene with a role in radioresistance. In:Radiation Research, M. Moriarty, C Mothersill, C Seymour, M Eddington, JF Ward, RJM Fry (eds.) Allen Press, Inc, Lawrence, Kansas pp 443 – 446.

Robson, C.N., Lohrer, H.D., Hoban, P.R., Johnston, C., Robson, T., Charlton, C., Reid, J., Harris, A.L., and Hickson, I.D. (1989) Characterisation of Chinese hamster ovary cell mutants hypersensitive to DNA damaging agents, In: DNA Repair mechanisms and Their Biological Implications in Mammalian cells,Lambert MW (eds), and Laval J (Plenum Press, New York) pp585 

invited editorials

Robson, T., West, C.  (2010) Radiation and the Genome: from risks to opportunities for therapeutic exploitationBr J Radiol. 83(992):635-7.PMID: 20647508.

Hirst, D.G., Robson, T.(2010) Molecular biology: the key to personalized treatment in radiation oncology? Br J Radiol.83(993):723-8. PMID: 20739343.

Robson, T., Hirst, D.G. (2008) Guest Editorial – Themed Issue: Radiation biology – can new concepts achieve better treatment outcomes? J Pharm Pharmacol. Sept. 60(9):1243-5. PMID: 18756613.

journal editorship

Robson, T. and Hirst, D.G. (2008) Special Issue: Radiation Biology – can new concepts achieve better treatment outcomes? J Pharm Pharmacol. 60(8)1–1110.